These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37761305)

  • 1. The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults.
    Wohlwend NF; Grossmann K; Aeschbacher S; Weideli OC; Telser J; Risch M; Conen D; Risch L
    Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of suPAR with lifestyle and cardiometabolic risk factors.
    Botha S; Fourie CM; Schutte R; Kruger A; Schutte AE
    Eur J Clin Invest; 2014 Jul; 44(7):619-26. PubMed ID: 24810168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
    Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
    Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.
    Gustafsson A; Ajeti V; Ljunggren L
    Biomark Insights; 2011; 6():119-25. PubMed ID: 22084570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms.
    Bigseth TT; Engh JA; Egeland J; Andersen E; Andreassen OA; Bang-Kittilsen G; Falk RS; Holmen TL; Lindberg M; Mordal J; Nielsen J; Steen NE; Ueland T; Vang T; Fredriksen M
    BMC Psychiatry; 2021 Oct; 21(1):527. PubMed ID: 34702245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study.
    Kokkinos A; Liaskos C; Alexiadou K; Papassotiriou I; Margeli A; Argyrakopoulou G; Perrea D; Alexandrou A; Katsilambros N; Diamantis T; Tentolouris N
    J Endocrinol Invest; 2021 Mar; 44(3):599-608. PubMed ID: 32681464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.
    Haupt TH; Kallemose T; Ladelund S; Rasmussen LJ; Thorball CW; Andersen O; Pisinger C; Eugen-Olsen J
    Biomark Insights; 2014; 9():91-100. PubMed ID: 25574132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
    Kurtipek GS; Kesli R; Tunçez Akyürek F; Akyüret F; Terzi Y
    Acta Dermatovenerol Alp Pannonica Adriat; 2015; 24(4):73-5. PubMed ID: 26697731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
    Hilty MP; Zügel S; Schoeb M; Auinger K; Dehnert C; Maggiorini M
    Mediators Inflamm; 2016; 2016():1942460. PubMed ID: 27378823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism.
    Joyce J; Cabanas N; Pisharody R; Ouyang B; Patel R; Reiser J; Hall DA; Witek N
    Parkinsonism Relat Disord; 2022 Aug; 101():39-42. PubMed ID: 35780693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.